13 results about "Cmv infections" patented technology

Provided herein are compositions and methods related to the treatment of a CMV infection and / or cancer in a subject.

This invention discloses a pCAMBIA1300-miniRNA3-BC-NLP Pya Vector and construction method and its application in high resistance to cucumber mosaic virus: The vector is miniRNA3-BC-NLP. Pya Construct the pCAMBIA1300 vector backbone, containing miniRNA3-BC and NLP. Pya The gene sequences are shown in SEQ ID NO:2 and 5. This invention discovered miniRNA3-BC-NLP. Pya It can effectively inhibit CMV infection and reduce the harm caused by CMV without the need for any drugs. It is a highly efficient and green disease control technology that can provide a new strategy for the prevention and control of cucumber mosaic virus and similar viruses.

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

The application provides a method for efficiently and stably inoculating tomatoes with cucumber mosaic virus, and relates to the technical field of crop disease-resistant breeding.The method for efficiently and stably inoculating tomatoes with cucumber mosaic virus comprises the following specific steps: S1, propagation: propagating CMV virus by using dcl 2 / 4i n.benthamiana; S2, extraction: extracting CMV virions; S3, inoculation: rubbing the tomatoes seedlings with the CMV virions in S2; and S4, cultivation: cultivating the tomatoes seedlings. The method significantly improves the efficiency and stability of CMV infection of tomatoes by using virions to infect the tomatoes seedlings. Furthermore, the dcl 2 / 4i n.benthamiana is used to propagate CMV virions, thereby shortening the propagation cycle of CMV virions, significantly improving the yield of CMV virions, and enabling repeated large-scale inoculation, which is conducive to efficient screening of CMV-resistant tomato varieties.

This invention discloses the application of the NbTuA gene in *Nicotiana benthamiana* in regulating plant resistance to turnip mosaic virus (CMV) and a method for cultivating transgenic plants. The NbTuA gene sequence is shown in SEQ ID NO:1. This invention involves cloning the NbTuA gene from *Nicotiana benthamiana* and constructing a vector fused with a YFP tag. Genetic transformation is then performed using Agrobacterium-mediated T-DNA transformation to construct transgenic plants of *Nicotiana benthamiana*. The *Nicotiana benthamiana* NbTuA transgenic plants obtained by this invention can significantly inhibit CMV infection.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and / or therapeutic immunotherapies based on cytotoxic T cell (CTL)-recognized T cell epitopes (e.g., CMV epitopes), and can be used to prevent and / or treat CMV infection, reactivation, and / or disease (e.g., CMV-associated end-organ disease), especially in solid organ transplant recipients.

The invention discloses a letemovir preparation composition which comprises the following components in percentage by weight: 20-70% of letemovir, 10-20% of filler, 10-20% of adhesive, 5-10% of disintegrating agent, 5-10% of flavoring agent, 5-10% of controlled release agent, 5-10% of lubricant, 5-10% of flow aid and 5-10% of solubilizer. 20%-70% of a filling agent; 2%-10% of an adhesive; 2%-10% of a disintegrating agent; 0.5%-5% of a flavoring agent; 0%-20% of a controlled release agent; 0.5%-5% of a lubricant; 0.5%-5% of a flow aid; and 0%-60% of a solubilizer. The Leltemovir granule can meet the requirements of prevention and treatment medication for children with dysphagia and old CMV (cytomegalovirus) infected patients without Leltemovir granules in China. The letemovir granules have the advantages of simple preparation process, stable process, better dissolution rate, good stability of finished products and the like, are suitable for industrial batch production, and can bring good social benefits and economic benefits.

The present invention discloses a novel recombinant polypeptide, and methods for stimulating protective or therapeutic immune responses to human herpesvirus. The invention relates to a composition comprising isolated homotrimers of a modified gB polypeptide from human cytomegalovirus (hCMV), wherein the gB polypeptide comprises an immunoglobulin signal peptide, an ex-tracellular domain with furin cleavage site mutations, and / or the intravirion domain, but lacks the transmembrane domain. Also the use thereof and methods of treating and preventing CMV associated disease or CMV infections with said composition.

Provided herein are compositions and methods for treating a virus-related disease or disorder. In certain instances, the compositions and methods are useful for treating CMV infection.

The present invention is directed to provide a modified CMV gB protein that can induce a group of antibodies including a high ratio of neutralizing antibodies that exhibit a high neutralizing activity against a CMV gB protein, in comparison with a wild type CMV gB, upon induction of immunity and that can be used in the prevention and / or treatment of CMV infection and a CMV vaccine comprising the modified CMV gB protein. The modified CMV gB protein according to the present invention is a modified CMV gB protein having an improved ability to induce body region-recognizing antibodies and comprising modification in a head region.

Provided herein are compositions and methods for treating a virus-related disease or disorder. In certain instances, the compositions and methods are useful for treating CMV infection.

The invention relates to the technical field of biology, in particular to a detection method and application of cytomegalovirus specific T cells. According to the detection method and application of the cytomegalovirus specific T cells, the method has the advantages of being stable in experimental result, high in specificity and sensitivity, easy to operate and the like, and CMV-CMI individualized monitoring of transplanted patients can be rapidly achieved. The method is helpful for accurately identifying CMV reactivation high-risk patients after hematopoietic stem cell transplantation. CMV reactivation layering prevention after transplantation is realized under the guidance of CMV-CMI, so that low-risk patients are prevented from being over-treated, and the sanitary economic cost is reduced; it is guaranteed that high-risk patients receive sufficient and sufficient treatment courses of treatment, an individualized CMV infection prevention strategy is formed, CMV reactivation after transplantation is prevented to the maximum extent, the non-relapse death rate after transplantation is reduced, and long-term survival of transplanted patients is improved.